Advanced search
Publication Cover
Pediatric Hematology and Oncology Volume 34, 2017 - Issue 2
Submit an article Journal homepage
262
Views
8
CrossRef citations to date
0
Altmetric
Non-Malignant Hematology

Encephaloduroarteriosynangiosis (EDAS) in young patients with cerebrovascular complications of sickle cell disease: Single-institution experience

Michael WinsteadDepartment of Hematology-Oncology, Children's Hospital and Research Center Oakland, Oakland, California, USA;Blood and Marrow Transplantation and Cellular Therapies Division, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, USACorrespondence[email protected]
,
Peter P. SunDepartment of Neurosurgery, Children's Hospital and Research Center Oakland, Oakland, California, USA
,
Kenneth MartinDepartment of Radiology, Children's Hospital and Research Center Oakland, Oakland, California, USA
,
Janice EarlDepartment of Hematology-Oncology, Children's Hospital and Research Center Oakland, Oakland, California, USA
,
Lynne NeumayrDepartment of Hematology-Oncology, Children's Hospital and Research Center Oakland, Oakland, California, USA
,
Carolyn HoppeDepartment of Hematology-Oncology, Children's Hospital and Research Center Oakland, Oakland, California, USA
&
Elliott VichinskyDepartment of Hematology-Oncology, Children's Hospital and Research Center Oakland, Oakland, California, USA
 show all
Pages 100-106 | Received 12 Oct 2016, Accepted 30 Jan 2017, Published online: 22 May 2017

References

  • Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91(1):288–294.
  • Bernaudin F, Verlhac S, Arnaud C, et al. Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort. Blood. 2011;117(4):1130–1140.
  • Sommet J, Alberti C, Couque N, et al. Clinical and haematological risk factors for cerebral macrovasculopathy in a sickle cell disease newborn cohort: a prospective study. Br J Haematol. 2016;172(6):966–977.
  • Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339(1):5–11.
  • Bader-Meunier B, Verlhac S, Elmaleh-Bergès M, et al. Effect of transfusion therapy on cerebral vasculopathy in children with sickle-cell anemia. Haematologica. 2009;94(1):123–126.
  • Hulbert ML, McKinstry RC, Lacey JL, et al. Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease. Blood. 2011;117(3):772–779.
  • Gyang E, Yeom K, Hoppe C, Partap S, Jeng M. Effect of chronic red cell transfusion therapy on vasculopathies and silent infarcts in patients with sickle cell disease. Am J Hematol. 2011;86(1):104–106.
  • Scott RM, Smith ER. Moyamoya disease and moyamoya syndrome. New Engl J Med. 2009;360(12):1226–1237.
  • Currie S, Raghavan A, Batty R, Connolly DJA, Griffiths PD. Childhood moyamoya disease and moyamoya syndrome: a pictorial review. Pediatr Neurol. 2011;44(6):401–413.
  • Moritani T, Numaguchi Y, Lemer NB, et al. Sickle cell cerebrovascular disease: usual and unusual findings on MR imaging and MR angiography. Clin Imaging. 2004;28(3):173–186.
  • Dobson SR, Holden KR, Nietert PJ, et al. Moyamoya syndrome in childhood sickle cell disease: a predictive factor for recurrent cerebrovascular events. Blood. 2002;99(9):3144–3150.
  • Hogan AM, Kirkham FJ, Isaacs EB, Wade AM, Vargha-Khadem F. Intellectual decline in children with moyamoya and sickle cell anaemia. Dev Med Child Neurol. 2005;47(12):824–829.
  • Fryer RH, Anderson RC, Chiriboga CA, Feldstein NA. Sickle cell anemia with moyamoya disease: outcomes after EDAS procedure. Pediatr Neurol. 2003;29(2):124–130.
  • Vernet O, Montes JL, O'Gorman AM, Baruchel S, Farmer JP. Encephaloduroarterio-synangiosis in a child with sickle cell anemia and moyamoya disease. Pediatr Neurol. 1996;14(3):226–230.
  • Hankinson TC, Bohman L-E, Heyer G, et al. Surgical treatment of moyamoya syndrome in patients with sickle cell anemia: outcome following encephaloduroarteriosynangiosis. J Neurosurg Pediatr. 2008;1(3):211–216.
  • Griessenauer CJ, Lebensburger JD, Chua MH, et al. Encephaloduroarteriosynangiosis and encephalomyoarteriosynangiosis for treatment of moyamoya syndrome in pediatric patients with sickle cell disease. J Neurosurg Pediatr. April 2015:1–10.
  • Stern TA, Rosenbaum JF, Fava M, Biederman J, Rauch SL. Massachusetts General Hospital Comprehensive Clinical Psychiatry: Expert Consult – Online and Print, 1e. 1 Har/Psc edition. Philadelphia, PA: Mosby; 2008.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.